Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04190888 · ClinicalTrials.gov registry record
Sickle Cell Uric Acid (SCUA) - Cohort Repository
A clinical trial of Sickle Cell Disease and Chronic Kidney Diseases, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 78
- Enrollment target
- 1
- Study location
NCT04190888: Completed study of Sickle Cell Disease and Chronic Kidney Diseases, sponsored by Virginia Commonwealth University.
NCT04190888 is a study of Sickle Cell Disease and Chronic Kidney Diseases that has completed, run by Virginia Commonwealth University. The registered enrollment target is 78 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04190888, a study of Sickle Cell Disease and Chronic Kidney Diseases, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the causes of Sickle Cell kidney disease, as well as to collect and store samples and information about people with Sickle Cell Disease.
Primary Outcome
(i.e. high uric acid levels) out of all patients with a uric acid level measured at baseline.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2021-12-31 |
What the finished NCT04190888 record still lists
NCT04190888 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04190888 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04190888 about?
NCT04190888 is a clinical study titled "Sickle Cell Uric Acid (SCUA) - Cohort Repository". The purpose of this research is to study the causes of Sickle Cell kidney disease, as well as to collect and store samples and information about people with Sickle Cell Disease.
What is the current status of trial NCT04190888?
This trial is currently completed. The enrollment target is 78 participants. The study started on 2019-07-01. Estimated completion is 2021-12-31.
What conditions does trial NCT04190888 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Chronic Kidney Diseases.
What interventions are being tested in trial NCT04190888?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04190888?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04190888 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04190888's enrollment target sits among peer trials
78 77th of 213 higher than 136 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI